Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study

被引:19
|
作者
Dauden, E. [1 ]
Pujol, R. M. [2 ]
Sanchez-Carazo, J. L. [3 ]
Toribio, J. [4 ]
Vanaclocha, F. [5 ]
Puig, L.
Yebenes, M. [6 ]
Sabater, E. [6 ]
Casado, M. A. [6 ]
Caloto, M. T. [2 ,7 ]
Aragon, B. [7 ]
机构
[1] Hosp La Princesa, Madrid, Spain
[2] Hosp Mar, Barcelona, Spain
[3] Hosp Gen Valencia, Valencia, Spain
[4] CHU Santiago Hosp Gil Casares, Santiago De Compostela, Spain
[5] Hosp 12 Octubre, Madrid, Spain
[6] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[7] Merck Sharp & Dohme Outcomes Res Unit, Madrid, Spain
来源
ACTAS DERMO-SIFILIOGRAFICAS | 2013年 / 104卷 / 09期
关键词
Psoriasis; Quality of life; Short-Form; 36; EuroQol-5D; Dermatology Life Quality Index; Psoriasis Disability Index;
D O I
10.1016/j.ad.2013.03.005
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis is associated with a deterioration in the health-related quality of life (HRQoL) of affected patients. The aim of this study was to assess the HRQoL of patients with moderate-to-severe psoriasis. Methods: A prospective observational study (the VACAP Study) was carried out in 123 centers in Spain with 1217 patients. Patients were evaluated at baseline (visit 1 [V1]) and again four months later (visit 2 [V2]). The severity of psoriasis was determined using the following indices: (i) Psoriasis Area and Severity Index (PASI) (score range 0-72, higher score indicates more severe disease), (ii) the body surface area (BSA) affected, and (iii) the Physicians Global Assessment (PGA) (range 1-7, higher score indicates more severe disease). Four questionnaires were used for the assessment of the HRQoL: (i) the Short-Form 36 quality-of-life questionnaire (SF-36) (score range 0-100, higher score indicates better HRQoL); (ii) Euroqol (EQ-5D) (range from 1 to 3, lower score indicates better HRQoL); (iii) Dermatology Life Quality Index (DLQI) (ranges 0-30; from best to worst HRQoL); and (iv) Psoriasis Disability Index (PDI) (ranges 0-45; higher score indicates better HRQoL). Results: The mean (SD) age of the patients was 45.11 (13.92) years at V1. The mean age at the onset of psoriasis was 26.08 (14.19) years. The majority of patients were female (61%) and were employed (68%). The mean PASI score was 13.24 (9.50) at V1 and 5.07 (6.03) at V2 (P<.001). Scores from the generic HRQoL questionnaires (EQ-5D. SF-36) showed significant improvement between visits in all dimensions measured (P<.001). The disease-specific questionnaires also revealed overall improvements in quality of life over time: the DLQI mean total score was 8.97 (7.28) at V1 and 4.76 (5.72) at V2 (P<.001), and the PDI mean total score was 9.24 (8.76) V1 and 4.88 (6.65) at V2 (P<.001). Multivariate analysis using PDI as the dependent variable showed that the principal factors related to HRQoL were severity of psoriasis as measured by PASI (P<.001), and gender (P=.048). Conclusions: The principal factor related to HRQoL in patients with psoriasis is the severity of the disease. (C) 2012 Elsevier Espana, S.L. and AEDV. All rights reserved.
引用
收藏
页码:807 / 814
页数:8
相关论文
共 50 条
  • [21] The Impact of Tofacitinib on Quality of Life in Patients with Moderate-to-Severe Psoriasis- An Observational Study
    Mohta, Alpana
    Nyati, Asha
    Ghiya, Bhikam Chand
    Mehta, Rajesh Dutt
    Jain, Suresh Kumar
    INDIAN JOURNAL OF DERMATOLOGY, 2023, 68 (03) : 354
  • [22] Health-Related Quality of Life in Patients with Psoriasis
    Jankovic, Slavenka
    Raznatovic, Milena
    Marinkovic, Jelena
    Jankovic, Janko
    Kocev, Nikola
    Tomic-Spiric, Vesna
    Vasiljevic, Nadja
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2011, 15 (01) : 29 - 36
  • [23] HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS WITH ABROCITINIB BY CLINICAL RESPONSE STATUS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Cork, Michael J.
    Hijnen, Dirk Jan
    Feeney, Claire
    Biswas, Pinaki
    Zhang, Fan
    Myers, Daniela E.
    DiBonaventura, Marco
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 49 - 50
  • [24] Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study
    Saibeni, S.
    Bezzio, C.
    Bossa, F.
    Privitera, A. C.
    Marchi, S.
    Roselli, J.
    Mazzuoli, S.
    Geccherle, A.
    Soriano, A.
    Principi, M. B.
    Viola, A.
    Sarpi, L.
    Cappello, M.
    D'Inca, R.
    Mastronardi, M.
    Bodini, G.
    Guerra, M.
    Benedetti, A.
    Romano, M.
    Cicala, M.
    Di Sabatino, A.
    Scaldaferri, F.
    De Rosa, T.
    Giardino, A. M.
    Germano, V.
    Orlando, A.
    Armuzzi, A.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (01) : 83 - 91
  • [25] Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study
    Hua Zhong
    Huan Yang
    Zhuxin Mao
    Xiaoyun Chai
    Shunping Li
    Health and Quality of Life Outcomes, 19
  • [26] Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study
    Zhong, Hua
    Yang, Huan
    Mao, Zhuxin
    Chai, Xiaoyun
    Li, Shunping
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2021, 19 (01)
  • [27] Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasis
    Feldman, SR
    Kimball, A
    Woolley, JM
    Zitnik, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P155 - P155
  • [28] Herbal Medicine Cordyceps sinensis Improves Health-Related Quality of Life in Moderate-to-Severe Asthma
    Wang, Ningqun
    Li, Jie
    Huang, Xiaobo
    Chen, Wenqiang
    Chen, Yujing
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, 2016
  • [29] HEALTH-RELATED QUALITY OF LIFE 5 YEARS AFTER MODERATE-TO-SEVERE TRAUMATIC BRAIN INJURY
    Andelic, Nada
    Roe, Cecilie
    JOURNAL OF NEUROTRAUMA, 2013, 30 (15) : A73 - A73
  • [30] Ustekinumab improves disease specific health-related quality of life in patients with moderate to severe psoriasis: Results with the dermatology life quality index
    Lebwohl, M.
    Papp, K.
    Schenkel, B.
    Eisenberg, D.
    Yeilding, N.
    Guzzo, C.
    Wang, Y.
    Li, S.
    Krueger, G. G.
    VALUE IN HEALTH, 2008, 11 (03) : A293 - A293